MarketCapExport financials
Neogen Corporation (NEOG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Neogen Corporation Financial Ratios 2026-2009 | NEOG
Brief overview of Neogen Corporation's multiples and efficiency
Current figures are compared with the company's own five-year history for 2018–2022.
Key multiples at the end of the period are P/E 50.76x (median 63.8x), EV/EBITDA 40.31x (median 40.31x), P/S 1.14x (median 4.65x). On average, this basket is 63.5% below its own five-year medians. The market values the business at a discount to recent history.
The inverse P/E implies an earnings yield of 2%. This is not a dividend yield, but current earnings relative to market price.
End-period return metrics are ROE -52.7%, ROA -31.7%, ROCE -51.2%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
The cash conversion cycle decreased 23.6 days to 150.4 days, supporting working-capital efficiency.
Valuation takeaway
Neogen Corporation's restrained price comes with modest current quality. Better efficiency is needed for revaluation.
Annual Financial Ratios Neogen Corporation
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-317.4 | -0.9 | -404.9 | -196.9 | 50.8 | 63.8 | 70.7 | 53.9 | 65.7 | 60.3 | 57.8 | 52.6 | 52.8 | 49.2 | 48.5 | 45.6 | 24.0 | - |
P/S |
2.9 | 1.1 | 4.1 | 5.5 | 4.7 | 8.3 | 10.1 | 7.8 | 10.3 | 7.3 | 6.6 | 6.2 | 6.0 | 6.4 | 5.9 | 6.0 | - | - |
EPS |
-0.0 | -5.0 | -0.0 | -0.1 | 0.5 | 0.6 | 0.6 | 0.6 | 1.2 | 0.9 | 0.7 | 0.9 | 0.8 | 0.8 | 0.6 | 1.0 | 0.3 | - |
EV (Enterprise Value) |
3.58 B | 2.26 B | 5.04 B | 5.76 B | 2.51 B | 3.89 B | 4.21 B | 3.26 B | 4.12 B | 2.62 B | 2.11 B | 1.74 B | 1.49 B | 1.32 B | 1.08 B | 1.04 B | 124 M | -13.8 M |
EBITDA per Share |
0.44 | -4.34 | 0.81 | 0.67 | 0.76 | 0.89 | 0.82 | 0.821 | 0.843 | 0.782 | 0.688 | 0.644 | 0.537 | 0.5 | 0.422 | 0.447 | 1.4 | - |
EV/EBITDA |
37.8 | -2.4 | 28.8 | 45.8 | 30.5 | 40.3 | 47.0 | 37.3 | 46.6 | 32.2 | 29.9 | 26.6 | 27.5 | 26.7 | 26.1 | 24.4 | 4.0 | - |
PEG |
2.11 | 0.01 | -701.33 | 47.62 | -262.41 | 11.7 | 13.83 | -9.66 | 1.57 | 3.39 | 7.42 | 2.95 | 30.48 | 2.65 | -13.02 | 1.64 | - | - |
P/B |
1.2 | 0.5 | 1.2 | 1.4 | 2.8 | 4.6 | 5.8 | 5.1 | 7.4 | 5.6 | 5.2 | 5.0 | 4.9 | 5.2 | 5.0 | 5.5 | 0.8 | - |
P/CF |
30.1 | 17.5 | 107.8 | 109.8 | 36.0 | 47.9 | 49.0 | 65.9 | 86.1 | 57.8 | 100.1 | 51.6 | 146.9 | 75.7 | 110.7 | 49.4 | 5.2 | - |
ROE % |
-0.38 | -52.72 | -0.30 | -0.73 | 5.44 | 7.24 | 8.20 | 9.43 | 11.27 | 9.29 | 9.05 | 9.55 | 9.19 | 10.53 | 10.29 | 12.11 | 3.99 | - |
ROA % |
-0.24 | -31.71 | -0.21 | -0.50 | 4.87 | 6.62 | 7.46 | 8.65 | 10.22 | 8.29 | 8.09 | 8.55 | 8.15 | 9.36 | 8.95 | 10.40 | 3.39 | - |
ROCE % |
-1.03 | -51.23 | 1.86 | 1.20 | 6.61 | 8.83 | 9.31 | 10.36 | 12.12 | 13.19 | 13.33 | 14.48 | 13.55 | 14.92 | 14.57 | 17.75 | 17.54 | - |
Current Ratio |
2.7 | 2.5 | 3.2 | 3.2 | 9.4 | 11.5 | 11.1 | 11.8 | 9.7 | 8.1 | 8.7 | 9.1 | 7.6 | 9.5 | 7.2 | 6.9 | - | - |
DSO |
62.9 | 66.6 | 64.4 | 56.1 | 66.3 | 68.8 | 73.0 | 72.8 | 71.8 | 69.2 | 76.9 | 76.3 | 76.6 | 68.1 | 70.7 | 60.5 | - | - |
DIO |
132.4 | 146.6 | 128.1 | 112.2 | 143.2 | 141.0 | 148.9 | 141.2 | 130.9 | 140.8 | 139.7 | 131.4 | 149.7 | 142.7 | 139.4 | 137.6 | - | - |
DPO |
62.7 | 62.7 | 63.3 | 48.8 | 37.6 | 35.7 | 36.8 | 31.3 | 35.7 | 31.3 | 34.3 | 34.9 | 39.2 | 34.3 | 42.9 | 36.6 | - | - |
Operating Cycle |
195.3 | 213.1 | 192.5 | 168.3 | 209.5 | 209.7 | 221.9 | 214.0 | 202.6 | 210.0 | 216.5 | 207.7 | 226.2 | 210.8 | 210.1 | 198.1 | - | - |
Cash Conversion Cycle |
132.6 | 150.4 | 129.2 | 119.6 | 171.9 | 174.1 | 185.1 | 182.7 | 166.9 | 178.7 | 182.3 | 172.8 | 187.1 | 176.5 | 167.2 | 161.5 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Neogen Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.08 | -0.07 | -0.08 | -0.07 | 0.17 | - | -0.05 | -2.1 | -0.06 | - | -0.01 | -0.02 | 0.01 | - | 0.04 | -0.19 | 0.05 | -0.23 | 0.05 | 0.1 | 0.16 | 0.26 | 0.13 | 0.15 | 0.15 | 0.3 | 0.12 | 0.15 | 0.14 | 0.31 | 0.28 | 0.31 | 0.29 | 0.31 | 0.29 | 0.33 | 0.23 | 0.33 | 0.31 | 0.22 | 0.2 | 0.29 | 0.26 | 0.24 | 0.25 | 0.24 | 0.25 | 0.21 | 0.24 | 0.21 | 0.24 | 0.17 | 0.22 | 0.17 | 0.33 | 0.19 | 0.19 | 0.29 | 0.28 | 0.22 | 0.26 | 0.22 | 0.26 |
EBITDA per Share |
0.38 | 0.24 | - | - | 0.06 | - | - | - | 0.15 | - | 0.16 | 0.18 | 0.22 | - | 0.18 | 0.07 | 0.11 | 0.29 | 0.08 | 0.14 | 0.26 | 0.43 | 0.15 | 0.18 | 0.22 | 0.54 | 0.25 | 0.35 | 0.4 | 0.52 | 0.4 | 0.35 | 0.4 | 0.52 | 0.4 | 0.35 | 0.4 | 0.51 | 0.53 | 0.33 | 0.48 | 0.63 | 0.48 | 0.39 | 0.47 | 0.54 | 0.33 | 0.35 | 0.43 | 0.49 | 0.43 | 0.27 | 0.4 | 0.38 | 0.6 | 0.29 | 0.5 | 0.58 | 0.5 | 0.35 | 0.46 | 0.47 | 0.46 |
ROE % |
-3.13 | -0.61 | -0.26 | -16.55 | -16.19 | -17.91 | -17.97 | -17.67 | -0.53 | -0.13 | 0.13 | -1.15 | -0.45 | -0.50 | -4.62 | -4.26 | -1.67 | -0.26 | 7.19 | 8.16 | 8.95 | 9.07 | 7.94 | 8.06 | 8.37 | 8.48 | 8.84 | 9.42 | 9.73 | 10.13 | 10.45 | 10.87 | 11.49 | 11.32 | 12.08 | 11.88 | 11.16 | 11.09 | 10.22 | 10.14 | 9.99 | 10.16 | 9.99 | 10.20 | 10.17 | 10.43 | 10.39 | 10.64 | 10.44 | 10.54 | 10.40 | 10.54 | 11.19 | 11.23 | 11.93 | 11.96 | 11.69 | 11.81 | 11.49 | 11.60 | 3.06 | 2.78 | 3.18 |
ROA % |
-1.96 | -0.38 | -0.17 | -10.92 | -10.73 | -11.80 | -11.85 | -11.65 | -0.37 | -0.09 | 0.09 | -0.78 | -0.17 | -0.20 | -3.89 | -3.52 | -1.48 | -0.18 | 6.54 | 7.44 | 8.20 | 8.30 | 7.14 | 7.26 | 7.55 | 7.66 | 7.95 | 8.40 | 8.66 | 9.01 | 9.27 | 9.61 | 10.13 | 9.93 | 10.44 | 10.24 | 9.58 | 9.52 | 8.86 | 8.79 | 8.65 | 8.81 | 8.66 | 8.82 | 8.82 | 9.04 | 9.04 | 9.25 | 9.05 | 9.10 | 8.91 | 8.97 | 9.55 | 9.58 | 10.16 | 10.19 | 9.90 | 9.97 | 9.68 | 9.75 | 2.64 | 2.23 | 2.64 |
ROCE % |
-0.82 | -1.43 | -0.97 | -17.95 | -17.62 | -16.87 | -16.48 | -16.23 | 1.52 | 1.45 | 1.95 | 1.32 | 1.55 | 0.94 | 0.76 | 0.99 | 2.68 | 4.53 | 8.78 | 9.93 | 10.97 | 10.94 | 9.52 | 9.48 | 9.64 | 9.59 | 9.80 | 10.52 | 10.91 | 11.28 | 11.67 | 12.06 | 12.49 | 13.03 | 13.59 | 14.13 | 14.55 | 14.71 | 15.06 | 15.08 | 14.91 | 15.27 | 15.09 | 14.90 | 14.97 | 15.11 | 15.15 | 16.03 | 15.52 | 15.84 | 15.37 | 15.72 | 16.63 | 16.55 | 17.53 | 17.44 | 17.04 | 17.24 | 16.75 | 16.93 | 4.47 | 4.04 | 4.64 |
Current Ratio |
2.7 | 2.7 | 2.7 | 2.7 | 2.7 | 2.5 | 2.9 | 2.9 | 3.3 | 3.2 | 3.2 | 3.2 | 3.2 | 3.2 | 3.3 | 3.1 | 10.4 | 9.4 | 9.3 | 9.6 | 12.2 | 11.5 | 11.5 | 12.4 | 11.7 | 11.7 | 12.6 | 12.6 | 11.8 | 13.0 | 12.5 | 11.3 | 10.8 | 11.4 | 11.1 | 9.6 | 9.1 | 10.3 | 9.7 | 9.3 | 9.1 | 10.6 | 9.8 | 8.9 | 9.4 | 10.3 | 9.9 | 9.3 | 9.2 | 9.4 | 9.2 | 8.4 | 8.2 | 9.9 | 9.6 | 8.4 | 8.3 | 8.3 | 8.0 | 7.5 | 7.3 | 7.6 | 7.4 |
DSO |
58.1 | 54.6 | 58.1 | 54.9 | 63.7 | - | 66.9 | 65.5 | 71.6 | - | 64.6 | 57.3 | 58.0 | - | 60.4 | 46.8 | 66.5 | 24.3 | 66.0 | 62.9 | 63.7 | 32.4 | 67.1 | 62.5 | 67.8 | 65.6 | 75.9 | 69.6 | 72.7 | 69.9 | 74.2 | 68.3 | 72.0 | 67.4 | 73.2 | 63.3 | 64.6 | 31.8 | 68.9 | 62.5 | 69.3 | 68.0 | 68.3 | 66.8 | 72.1 | 67.9 | 67.8 | 69.2 | 69.9 | 69.2 | 65.9 | 68.5 | 64.2 | 59.3 | 59.5 | 67.7 | 67.3 | 64.1 | 62.0 | 65.6 | 61.2 | 58.2 | - |
DIO |
131.9 | 125.5 | 131.9 | 137.7 | 153.5 | - | 166.4 | 153.5 | 157.9 | - | 139.8 | 121.8 | 111.6 | - | 115.8 | 103.0 | 163.6 | 57.3 | 142.0 | 136.5 | 135.5 | 66.5 | 140.2 | 140.4 | 148.9 | 136.1 | 146.9 | 139.9 | 148.9 | 138.2 | 141.8 | 126.5 | 133.5 | 121.5 | 135.6 | 127.8 | 135.4 | 65.5 | 139.1 | 137.0 | 141.9 | 124.6 | 133.0 | 129.6 | 132.6 | 113.8 | 138.2 | 144.7 | 144.6 | 136.4 | 134.1 | 138.0 | 132.9 | 116.1 | 124.2 | 142.9 | 137.5 | - | - | - | - | - | - |
DPO |
56.2 | 53.5 | 56.2 | 54.0 | 62.4 | - | 62.6 | 54.6 | 58.9 | - | 82.3 | 81.8 | 67.8 | - | 57.8 | 41.3 | 40.1 | 14.2 | 37.2 | 37.0 | 30.9 | 15.8 | 32.4 | 31.9 | 37.2 | 33.0 | 32.3 | 30.5 | 32.1 | 30.6 | 34.0 | 33.1 | 35.9 | 33.2 | 34.6 | 29.6 | 30.4 | 14.5 | 32.2 | 34.1 | 35.7 | 30.6 | 38.6 | 39.1 | 35.0 | 30.2 | 32.9 | 32.4 | 35.9 | 35.7 | 33.7 | 34.9 | 33.8 | 27.9 | 28.5 | 34.6 | 39.5 | - | - | - | - | - | - |
Operating Cycle |
- | - | 190.1 | 192.6 | 217.2 | - | 233.3 | 219.0 | 229.6 | - | 204.4 | 179.0 | 169.6 | - | 176.2 | 149.7 | 230.1 | 81.6 | 208.0 | 199.3 | 199.2 | 98.8 | 207.4 | 202.9 | 216.7 | 201.7 | 222.8 | 209.5 | 221.6 | 208.1 | 216.0 | 194.8 | 205.5 | 188.9 | 208.9 | 191.0 | 200.0 | 97.2 | 208.0 | 199.5 | 211.1 | 192.7 | 201.3 | 196.5 | 204.6 | 181.6 | 206.0 | 213.8 | 214.6 | 205.5 | 200.0 | 206.5 | 197.1 | 175.4 | 183.6 | 210.6 | 204.8 | 64.1 | 62.0 | 65.6 | 61.2 | 58.2 | - |
Cash Conversion Cycle |
- | - | 133.9 | 138.6 | 154.8 | - | 170.7 | 164.4 | 170.7 | - | 122.1 | 97.2 | 101.7 | - | 118.4 | 108.5 | 190.0 | 67.4 | 170.8 | 162.4 | 168.2 | 83.1 | 175.0 | 171.0 | 179.4 | 168.7 | 190.6 | 179.0 | 189.5 | 177.5 | 182.0 | 161.7 | 169.6 | 155.7 | 174.3 | 161.4 | 169.6 | 82.7 | 175.8 | 165.4 | 175.4 | 162.1 | 162.8 | 157.4 | 169.6 | 151.4 | 173.1 | 181.4 | 178.6 | 169.8 | 166.3 | 171.6 | 163.3 | 147.5 | 155.1 | 176.0 | 165.3 | 64.1 | 62.0 | 65.6 | 61.2 | 58.2 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Neogen Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |